Modulim Company Profile

Background

Modulim is a health technology company dedicated to preserving tissue health by empowering clinicians with actionable microvascular and data insights for the lower limb. Founded by Dr. David J. Cuccia, the inventor of Spatial Frequency Domain Imaging (SFDI), Modulim focuses on delivering non-invasive imaging solutions that enhance patient outcomes, particularly for individuals with diabetes, kidney disease, and peripheral arterial disease. The company's flagship product, the Clarifi® Imaging System, utilizes SFDI technology to provide rapid, non-contact microvascular assessments at the point of care.

Key Strategic Focus

Modulim's strategic objectives include:

Advancing Non-Invasive Imaging Solutions: Developing and deploying SFDI-based technologies to assess tissue oxygenation and perfusion, aiding in the early detection and management of circulatory complications.

Enhancing Clinical Workflow: Integrating imaging solutions with data management platforms like Modulim Cloud™ and Magnifi to streamline clinical workflows and facilitate proactive, data-driven decision-making.

Targeting High-Risk Populations: Focusing on patients with chronic conditions such as diabetes, kidney disease, and peripheral arterial disease, who are at elevated risk for lower limb complications.

Expanding Market Reach: Pursuing regulatory approvals and strategic partnerships to broaden the adoption of Modulim's technologies in domestic and international markets.

Financials and Funding

Modulim has secured funding from a combination of grants and private venture capital to support its research, development, and commercialization efforts. Notable investors include Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK. The capital raised has been utilized to advance product development, obtain regulatory clearances, and expand market presence.

Pipeline Development

Modulim's product pipeline centers around the Clarifi® Imaging System and its associated software solutions:

Clarifi® Imaging System: An FDA-cleared and CE-marked device that provides non-contact, rapid microvascular assessments to identify compromised circulation.

Modulim Cloud™: A data management platform that enables timely, proactive, data-driven decisions by digitally connecting clinicians and healthcare systems.

Magnifi: A clinical workflow software launched in November 2022, designed to enhance clinical efficiency, improve workflow, and assist clinicians in patient management.

These products are aimed at reducing lower-limb complications and improving patient outcomes through early detection and intervention.

Technological Platform and Innovation

Modulim's proprietary technology is centered on Spatial Frequency Domain Imaging (SFDI), a non-invasive optical imaging technique that quantifies tissue oxygenation and hemoglobin distribution. Key aspects include:

Proprietary Technologies: SFDI enables the measurement of tissue health biomarkers by analyzing light absorption and scattering, providing clinicians with detailed insights into microvascular function.

Scientific Methodologies: The technology differentiates between tissue layers and components, allowing for precise assessment of tissue oxygenation and perfusion without exposing patients to harmful radiation.

AI-Driven Capabilities: While specific AI applications are not detailed, Modulim's data management platforms, such as Modulim Cloud™ and Magnifi, facilitate data-driven decision-making and workflow optimization.

Leadership Team

Charlie Huiner, M.B.A.: President and Chief Executive Officer

Over 25 years of executive experience in healthcare, including roles at Sientra, Inc. and InTouch Health.

Expertise in corporate growth strategies, financing, and team building.

Amaan Mazhar, Ph.D.: Chief Product Officer

Background in Bioengineering and Biomedical Engineering, with a focus on SFDI.

Over 50 publications and several patents in biophotonics.

Andre Grujovski, M.B.A.: Vice President, Marketing

15 years of marketing experience in healthcare, specializing in integrated marketing strategies for emerging markets.

Formerly at InTouch Health, contributing to marketing organization growth and successful acquisition.

David J. Cuccia, Ph.D.: Founder and Chief Technology Officer

Inventor of SFDI, with a Ph.D. in Biomedical Engineering from UC Irvine.

Secured over $21 million in funding and holds multiple patents in biomedical optics.

Gary Marston, M.S.: Vice President, Sales

Over two decades of experience in medical device sales, marketing, and operations.

Background includes roles at Masimo, R2 Technology, and Eli Lilly.

Leadership Changes

In May 2022, Modulim appointed Carl St. Bernard to its Board of Directors. Mr. St. Bernard brings over 25 years of experience in medical technology leadership, including roles at CeloNova Biosciences and Tryton Medical.

Competitor Profile

Market Insights and Dynamics

The market for non-invasive vascular assessment technologies is driven by the increasing prevalence of chronic conditions such as diabetes, kidney disease, and peripheral arterial disease. Approximately 61 million people in the U.S. are at risk for lower limb complications due to these conditions. The demand for early detection and management solutions is growing, emphasizing the need for innovative technologies like those offered by Modulim.

Competitor Analysis

Key competitors in the non-invasive vascular assessment market include:

Perimed AB: Specializes in laser Doppler and laser speckle contrast imaging systems for microcirculation assessment.

ViOptix Inc.: Offers tissue oximetry devices for assessing tissue oxygenation in reconstructive surgery.

Sotera Wireless: Develops continuous non-invasive monitoring solutions for vital signs, including blood pressure and oxygen saturation.

These companies focus on various aspects of vascular health assessment, utilizing different technologies to address specific clinical needs.

Strategic Collaborations and Partnerships

Modulim has established significant partnerships to enhance its market position and innovation capacity:

Satellite Healthcare: In July 2022, Modulim partnered with Satellite Healthcare to implement the Limb Assessment, Management, and Preservation (LAMP) solution across dialysis and vascular access centers, aiming to reduce lower limb ulcers and amputations.

U.S. Army Medical Materiel Development Activity: In May 2023, Modulim was awarded a $2.5 million contract to develop a handheld digital burn assessment tool, expanding the application of its SFDI technology.

Operational Insights

Modulim's strategic considerations include:

Market Position: Leveraging its proprietary SFDI technology to offer unique, non-invasive solutions for microvascular assessment, differentiating itself from competitors.

Competitive Advantages: The ability to provide rapid, non-contact assessments with detailed tissue health insights positions Modulim favorably in the market.

Regulatory Approvals: Achieving FDA clearance and CE marking for the Clarifi® Imaging System facilitates market expansion and adoption.

Strategic Opportunities and Future Directions

Modulim's strategic roadmap includes:

Product Development: Continuing to innovate and expand the capabilities of the Clarifi® Imaging System and associated software solutions.

Market Expansion: Pursuing additional regulatory approvals and partnerships to enter new geographic markets.

Clinical Integration: Enhancing integration with electronic health records and clinical workflows to streamline adoption and utilization.

Research and Development: Investing in R&D to explore new applications of SFDI technology in various medical fields.

Contact Information

For more information, visit Modulim's official website.

Please note that specific contact details such as address, phone number, or email are not provided in this profile.